Viking initiates study to evaluate dual GLP-1/GIP receptor agonist VK2735
Viking Therapeutics has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like...
top of page
Browse by category
Search
AMGEN presents ‘encouraging’ AMG 133 weight loss results
Amgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...
STEP 8: Greater weight loss for once-weekly semaglutide vs daily liraglutide
Once-weekly subcutaneous semaglutide (2.4mg) is more effective on weight loss in conjunction with counselling and physical activity vs...
Browse by tag
bottom of page